tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2023 Mar 21;17(3):e13116.
doi: 10.1111/irv.13116. eCollection 2023 Mar.
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial
Faizah Alotaibi[SUP] 1 [/SUP], Naif Khalaf Alharbi[SUP] 2 [/SUP], Lindsey B Rosen[SUP] 3 [/SUP], Ayed Y Asiri[SUP] 4 [/SUP], Abdullah M Assiri[SUP] 5 [/SUP], Hanan H Balkhy[SUP] 6 [/SUP], Majed Al Jeraisy[SUP] 2 [/SUP], Yasser Mandourah[SUP] 7 [/SUP], Sameera AlJohani[SUP] 2 8 [/SUP], Shmeylan Al Harbi[SUP] 2 9 [/SUP], Hani A Aziz Jokhdar[SUP] 5 [/SUP], Ahmad M Deeb[SUP] 2 [/SUP], Ziad A Memish[SUP] 10 [/SUP], Jesna Jose[SUP] 2 [/SUP], Sameeh Ghazal[SUP] 4 [/SUP], Sarah Al Faraj[SUP] 7 [/SUP], Ghaleb A Al Mekhlafi[SUP] 7 [/SUP], Nisreen Murad Sherbeeni[SUP] 7 [/SUP], Fatehi Elnour Elzein[SUP] 7 [/SUP], Badriah M AlMutairi[SUP] 2 [/SUP], Abdulaziz Al-Dawood[SUP] 2 11 [/SUP], Mashan L Abdullah[SUP] 12 [/SUP], Tlili Barhoumi[SUP] 2 [/SUP], Mohammed W Alenazi[SUP] 2 [/SUP], Abdulrahman Almasood[SUP] 2 [/SUP], Steven M Holland[SUP] 3 [/SUP], Yaseen M Arabi[SUP] 2 11 [/SUP]; Saudi Critical Care Trials Group
Affiliations
Abstract
Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto-Abs) to type I IFNs were reported as a risk factor for life-threatening COVID-19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS).
Methods: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay.
Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups.
Conclusion: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS.
Keywords: ICU; MERS; MIRACLE trial; Type I IFNs; auto‐abs.
. 2023 Mar 21;17(3):e13116.
doi: 10.1111/irv.13116. eCollection 2023 Mar.
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial
Faizah Alotaibi[SUP] 1 [/SUP], Naif Khalaf Alharbi[SUP] 2 [/SUP], Lindsey B Rosen[SUP] 3 [/SUP], Ayed Y Asiri[SUP] 4 [/SUP], Abdullah M Assiri[SUP] 5 [/SUP], Hanan H Balkhy[SUP] 6 [/SUP], Majed Al Jeraisy[SUP] 2 [/SUP], Yasser Mandourah[SUP] 7 [/SUP], Sameera AlJohani[SUP] 2 8 [/SUP], Shmeylan Al Harbi[SUP] 2 9 [/SUP], Hani A Aziz Jokhdar[SUP] 5 [/SUP], Ahmad M Deeb[SUP] 2 [/SUP], Ziad A Memish[SUP] 10 [/SUP], Jesna Jose[SUP] 2 [/SUP], Sameeh Ghazal[SUP] 4 [/SUP], Sarah Al Faraj[SUP] 7 [/SUP], Ghaleb A Al Mekhlafi[SUP] 7 [/SUP], Nisreen Murad Sherbeeni[SUP] 7 [/SUP], Fatehi Elnour Elzein[SUP] 7 [/SUP], Badriah M AlMutairi[SUP] 2 [/SUP], Abdulaziz Al-Dawood[SUP] 2 11 [/SUP], Mashan L Abdullah[SUP] 12 [/SUP], Tlili Barhoumi[SUP] 2 [/SUP], Mohammed W Alenazi[SUP] 2 [/SUP], Abdulrahman Almasood[SUP] 2 [/SUP], Steven M Holland[SUP] 3 [/SUP], Yaseen M Arabi[SUP] 2 11 [/SUP]; Saudi Critical Care Trials Group
Affiliations
- PMID: 36960162
- PMCID: PMC10028524
- DOI: 10.1111/irv.13116
Abstract
Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto-Abs) to type I IFNs were reported as a risk factor for life-threatening COVID-19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS).
Methods: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay.
Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups.
Conclusion: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS.
Keywords: ICU; MERS; MIRACLE trial; Type I IFNs; auto‐abs.